Equities

Hainan Huluwa Pharmaceutical Group Co Ltd

605199:SHH

Hainan Huluwa Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.93
  • Today's Change0.36 / 3.41%
  • Shares traded7.44m
  • 1 Year change-25.70%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments521464473
Total Receivables, Net622474367
Total Inventory266214213
Prepaid expenses297919
Other current assets, total5.221715
Total current assets1,4431,2471,087
Property, plant & equipment, net1,305842529
Goodwill, net120--
Intangibles, net255157136
Long term investments2020--
Note receivable - long term------
Other long term assets------
Total assets3,0612,3121,761
LIABILITIES
Accounts payable18193104
Accrued expenses778157
Notes payable/short-term debt436548486
Current portion long-term debt/capital leases1214.6352
Other current liabilities, total26833094
Total current liabilities1,0831,057794
Total long term debt7391784.10
Total debt1,297731542
Deferred income tax2.95----
Minority interest391.382.32
Other liabilities, total766132
Total liabilities1,9401,298833
SHAREHOLDERS EQUITY
Common stock400400400
Additional paid-in capital291291291
Retained earnings (accumulated deficit)430323238
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,1201,014928
Total liabilities & shareholders' equity3,0612,3121,761
Total common shares outstanding400400400
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.